Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.57 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325876 | 1.00 | CCR3 (0.57) | CCR3FPR2PROKR1FBP1SSTR5 | |
| SCHEMBL6325871 | 1.00 | CCR3 (0.57) | CCR3FPR2PROKR1FBP1SSTR5 | |
| SCHEMBL6326947 | 0.93 | CCR3 (0.57) | CCR3FPR2PROKR1FBP1SSTR5 | |
| SCHEMBL6326943 | 0.93 | CCR3 (0.57) | CCR3FPR2PROKR1FBP1SSTR5 | |
| SCHEMBL6326938 | 0.93 | CCR3 (0.57) | CCR3FPR2PROKR1FBP1SSTR5 | |
| SCHEMBL6325977 | 0.90 | CCR3 (0.54) | CCR3FPR2PROKR1SSTR5HRH1 | |
| SCHEMBL6325973 | 0.90 | CCR3 (0.54) | CCR3FPR2PROKR1SSTR5HRH1 | |
| SCHEMBL6325978 | 0.90 | CCR3 (0.54) | CCR3FPR2PROKR1SSTR5HRH1 | |
| SCHEMBL6327582 | 0.90 | CCR3 (0.52) | CCR3SSTR5HRH1HTR2B | |
| SCHEMBL6327587 | 0.90 | CCR3 (0.52) | CCR3SSTR5HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | CCR3 2/4885FPR2 81/4885PROKR1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.